SCIENTIFIC REPORT 2010 - 2011 - IOV

More documents

Recommendations

Info

Major Collaborations Multidisciplinary Teams of Disease The Clinical Oncology 1 participates in multidisciplinary teams for studying cancers of the rectum, sarcomas, liver metastases, urologic tumors, brain tumors, breast cancer, liver tumors and peritoneal carcinomatosis. Within the <strong>IOV</strong>, steady interactions involve: Clinical Oncology 2, Molecular Immunology and Oncology, Surgery, Endocrinology, Radiotherapy and Nuclear Medicine, Psycho- Oncology, Cardiology, Radiology, Endoscopy, Pathology. National Collaborations Azienda Ospedaliera-Università, Padova Ulss 16, Padova CNR Aging Center, Padova Istituto Mario Negri (Milano) Istituto Nazionale Tumori (Milano) Istituto Humanitas (Milano) Istituto S. Raffaele (Milano) CRO (Aviano) Oncologia Medica (Pisa) Oncologia Medica (Ancona) Oncologia Medica Niguarda (Milano) IRST Meldola (Forlì) INRCA-Roma Neuro-oncologia, Università Torino Istituto Besta (Milano) Oncologia Medica (Verona) Oncologia Medica (Rovigo) Oncologia Medica (Vicenza) THE DEPARTMENTS - DEPARTMENT OF CLINICAL ONCOLOGY 38 National Working Groups: GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente) Mango (Mario Negri Gynecologic Oncology Group) ISG (Italian Sarcoma Group) GUONE (Gruppo Uro-oncologico del Nord Est) International Collaborations SENDO - Southern Europe New Drug Organization (Dott. Silvia Marsoni) New York University, Clinical Cancer Center, New York (Prof. F. Muggia) UCSF Medical Center, San Francisco (Prof. S. Chang) Memorial Sloan-Kettering Cancer Center, New York (Dr. A. Omuro) University of Losanne (Prof. R. Stupp) Division of Medical Genetics, Department of Medicine, Abramson Cancer Center, University of Pennsylvania (Prof. Katherine L. Nathanson) EORTC brain group EORTC elderly group EORTC sarcoma group
Major Ongoing Research Projects NEw ThErapEuTiC STraTEGiES iN ThE TrEaTmENT Of GaSTrO-iNTESTiNal (Gi) TumOrS Principal Investigators: Sara Lonardi, Davide Pastorelli, Vittorina Zagonel The management of GI tract cancers (both colorectal and non-colorectal) has widely changed over the last years, switching from a “tumor” perspective to a “patient’s tailored” approach. Identification of prognostic and predictive markers, optimization of multidisciplinary strategies, and new targeted drug development are some of the major points of interest for clinical and experimental research. Several trials are currently ongoing at our Institution in collaboration with multidisciplinary groups of Padua and others Oncology Units and national groups. A. prOGNOSTiC aND prEDiCTivE faCTOrS The identification of patients characterized by a worse prognosis or by a higher probability of response to certain treatments is crucial to select the “better population” for the “better therapeutic strategy”, and it is one of the main areas of research at our Institution. Molecular factors predictive of response to pre-operative chemo-radiation in locally advanced rectal cancer. Pre-operative chemo-radiotherapy (pCRT) approach for locally advanced rectal cancer is worldwide accepted as a standard treatment. The prediction of response to CRT has the potential to spare unnecessary toxic treatments for non-responders and, in selected cases, to allow a conservative surgery (local excision). Multiple patient- and tumor-related factors have been evaluated as potential predictors of response, but few studies take the tumor biology into account. Patients with rectal cancer, candidate to receive the same schedule of pCRT will be prospectively evaluated to assess the correlation of carcinoembryonic antigen (CEA), cell-free circulating DNA (cfDNA), levels of telomerase reverse transcriptase (h-TERT) and circulating tumor cells (CTC) with pathological response after pCRT and disease recurrence. Pharmacogenetic profiling and clinical outcome of patients with high-risk stage II and III colon cancer treated with adjuvant FOLFOX-4/XELOX chemotherapy and bevacizumab. Oxaliplatin plus a fluoropyrimidine (FOLFOX/XELOX) is THE DEPARTMENTS - DEPARTMENT OF CLINICAL ONCOLOGY 39 the worldwide standard adjuvant therapy for high-risk stage II and III colorectal cancer, but the optimal duration of therapy and the management of toxicities remain to be resolved. Hopefully, it would be useful to find predictive/prognostic markers that could allow future adjuvant strategies to be optimized and individualized. Genomic polymorphisms in drug target genes, genes encoding DNA-repair enzymes and detoxification pathways may influence the activity of 5-Fluorouracil/capecitabine and Oxaliplatin, and their identification may improve the tailoring of chemotherapy and the choice of the optimal treatment strategy. In the present multicenter study, a panel of 17 polymorphisms within eleven genes in patients with radically resected high-risk stage II and III colon cancer undergoing adjuvant FOLFOX-4/ XELOX chemotherapy and bevacizumab within a prospective phase III randomized clinical trial will be evaluated. Prospective evaluation of -1498 C/T VEGF polymorphism in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer patients. Many studies have demonstrated that specific VEGF single nucleotide polymorphisms (SNPs) may affect gene transcription with a consequent variable production of VEGF and a probable indirect effect on pathogenesis and evolution of several disorders in which angiogenesis may be critical. Patients bearing -1498 T/T genotype had significantly shorter progression-free survival (PFS) and worse, but not statistically significant, overall survival (OS) compared to patients carrying at least one C allele. On this basis we planned to prospectively evaluate the potential predictive role of -1498 C/T VEGF polymorphism in CRC patients treated with first-line FOLFIRI plus Bevacirumab. Primary objective is to evaluate the correlation between -1498 C/T VEGF allelic variants and first-line PFS, while the secondary objectives is to evaluate the correlation with response rate, overall survival and toxicities attributable to Bevacizumab. B. OpTimizaTiON Of ThE TimiNG Of aDiuvaNT ChEmOThErapy Gastric and pancreatic cancers are a major cause of mortality worldwide. Prognosis is poor unless the cancer is diagnosed at a very early stage. Therapeutic options for patients with stage I-III gastric and pancreatic cancer include surgery plus adjuvant chemotherapy with or without radiotherapy, but the optimal
Page 1: SCIENTIFIC REPORT 2010 - 2011 ISTIT
Page 4 and 5: Line 5 - Tumor Immunology and Innov
Page 6 and 7: This volume is the third edition of
Page 9 and 10: THE INSTITUTE THE INSTITUTE 9
Page 11 and 12: Aerial view of the Busonera area TH
Page 13 and 14: Chief Officer Address THE INSTITUTE
Page 16 and 17: The IOV Governance The IOV is gover
Page 18 and 19: GENERAL DIRECTORATE Pier Carlo Muzz
Page 21 and 22: Chief Medical Officer Report CLINIC
Page 23 and 24: to interact with other IRCCS to pro
Page 25 and 26: DRG average relative weight 4,5 4,0
Page 27 and 28: Radiation treatments 1200 1000 800
Page 29 and 30: The experts of these groups meet at
Page 31 and 32: THE DEPARTMENTS THE DEPARTMENTS 31
Page 33 and 34: Department of Clinical Oncology THE
Page 35 and 36: Clinical and Research Staff Vittori
Page 37: Clinical Activity Distribution of p
Page 41 and 42: of Ramucirumab using a double-blind
Page 43: events has been planned in order to
Page 46 and 47: Main Pubblications Clinical Oncolog
Page 48 and 49: Mission The mission of this Unit is
Page 50 and 51: Major Ongoing Research Projects iDE
Page 52: NEw ThErapEuTiC STraTEGiES iN ThE T
Page 55 and 56: Clinical and Research Staff Antonio
Page 57 and 58: Department of Surgery THE DEPARTMEN
Page 59 and 60: Clinical and Research Staff Carlo C
Page 61 and 62: Major Research Collaborations Insid
Page 64 and 65: Main Pubblications Chief Breast Sur
Page 66 and 67: Mission The mission of the Breast S
Page 68 and 69: Main Pubblications Melanoma and Sof
Page 70 and 71: Mission The Melanoma and Soft Tissu
Page 72 and 73: National Collaborations Italian Sar
Page 74 and 75: express bioluminescent or fluoresce
Page 76 and 77: Diagnostic and Operative Endoscopy
Page 78 and 79: Mission The mission of the Unit is
Page 80 and 81: Major Ongoing Research Projects frO
Page 82 and 83: Main Pubblications Chief Comparison
Page 85 and 86: Mission The mission of the Unit of
Page 87 and 88: late (occurring after the first che
Page 89 and 90:
Department of Imaging, Radiology &
Page 91 and 92:
Clinical and Research Staff Fabio P
Page 93 and 94:
Major Ongoing Research Projects Dif
Page 96 and 97:
Main Pubblications Chief Correlatio
Page 98 and 99:
Mission The Breast Imaging Unit mis
Page 100 and 101:
Regarding the new HIBRC2 study, the
Page 102 and 103:
Methods. Patient accrual, following
Page 104 and 105:
Mission and Clinical Activity The m
Page 107 and 108:
Department of Radiotherapy & Nuclea
Page 109 and 110:
Clinical and Research Staff Guido S
Page 111 and 112:
Clinical Activity The acquisition o
Page 113 and 114:
Areas of Excellence Thyroid cancer
Page 115 and 116:
Fig. 2. The thick Beryllium target,
Page 117 and 118:
field and the Nuclear Medicine Serv
Page 120 and 121:
Main Pubblications Chief Medical Ph
Page 122 and 123:
Mission To assure safe, accurate an
Page 124 and 125:
Other Programs and Future Perspecti
Page 127 and 128:
Department of Experimental, Laborat
Page 129 and 130:
Clinical and Research Staff Annaros
Page 131 and 132:
Analyses for solid tumors by year A
Page 133 and 134:
egard, the activity of some researc
Page 135 and 136:
to high-risk families; b) assessmen
Page 137 and 138:
with plasmids expressing either p16
Page 139 and 140:
The results published so far indica
Page 141 and 142:
levels of h-TERT mRNA increased wit
Page 143 and 144:
More recently, given that the real
Page 145 and 146:
aDvaNCED appliCaTiONS Of CirCulaTiN
Page 147 and 148:
the persistence of more aggressive
Page 149 and 150:
phosphokinome will be investigated
Page 151 and 152:
algorithm that takes into account t
Page 153 and 154:
samples. Except for 13q deletions,
Page 155 and 156:
Clinical and Research Staff Giusepp
Page 157 and 158:
Figure 1. the tumor of the adrenal
Page 159 and 160:
goal of this project is to use a co
Page 161 and 162:
Department of Services THE DEPARTME
Page 163 and 164:
Clinical and Research Staff Angelo
Page 165 and 166:
according to the onco-AIFA Registry
Page 168 and 169:
Main Pubblications Chief Alberto Ba
Page 170 and 171:
Mission This Unit is mainly devoted
Page 172 and 173:
Main Pubblications Chief Positive e
Page 174 and 175:
Mission The Psycho-oncology Service
Page 176 and 177:
An ad hoc intervention has therefor
Page 178 and 179:
Main Pubblications Chief Cancer pre
Page 180 and 181:
Mission The main aims of the Veneto
Page 182:
Population and Social Policies. Thi
Page 187 and 188:
Scientific Director Address THE RES
Page 189 and 190:
e transferred from the bench to bed
Page 191 and 192:
Scientific Directorate Organization
Page 193 and 194:
library Responsible: Mauro Apostoli
Page 195 and 196:
In the awareness of the difficult t
Page 197 and 198:
Research: Input and Output The rese
Page 199 and 200:
strategic focus for the Government
Page 201 and 202:
Impact Factor Trend 1000 800 600 40
Page 203 and 204:
Clinical and Research Staff Gian Lu
Page 205 and 206:
International Collaborations Emma C
Page 209 and 210:
Strategic Scientific Options THE RE
Page 211 and 212:
approaches are tested at the IOV wi
Page 213 and 214:
Thiopurine S-methyltransferase (TPM
Page 215 and 216:
of specific functional features of
Page 217 and 218:
RESEARCH ACTIVITY REPORT RESEARCH A
Page 219 and 220:
N° Prog Titolo Responsabile L01P01
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
L03P44 L03P45 L03P46 L03P47 L03P48
Page 227 and 228:
Page 229 and 230:
L04P39 Chemioterapia adiuvante in p
Page 231 and 232:
Page 233 and 234:
Progr. Titolo Responsabile L06P01 L
Page 235 and 236:
CLINICAL RESEARCH CLINICAL RESEARCH
Page 237 and 238:
Numerous phase II and III, sponsore
Page 239 and 240:
A Multicenter phase III trial to ev
Page 241 and 242:
LUNG An International multicenter r
Page 243:
A randomized, double-blind, placebo
Page 246 and 247:
Veneto Oncology Network The Istitut
Page 248 and 249:
Building a network is not a trivial
Page 250 and 251:
Internal Education & Training The I
Page 252 and 253:
La comunicazione interpersonale neg
Page 254 and 255:
Trattamento del dolore cronico nel
Page 256 and 257:
EDUCATION 256
Page 258 and 259:
Charles R M Bangham How does HTLV-1
Page 261:
AWARDS VENETO ONCOLOGY AWARDS NETWO
Page 265 and 266:
PUBLICATIONS PUBLICATIONS 265
Page 267 and 268:
carcinoma with singular bone metast
Page 269 and 270:
46 Ciccolallo L, Licitra L, Cantù
Page 271 and 272:
P, Rubeca T, Zappa M. Immunochemica
Page 273 and 274:
113 Novara G, De Marco V, Aragona M
Page 275 and 276:
4-mercaptophenol derivative designe
Page 277 and 278:
Use of a manual dermatoscope with a
Page 279 and 280:
Cancer Genetics Network, Thomassen
Page 281 and 282:
33 Cecchin D, Schiavi F, Fanti S, F
Page 283 and 284:
of diphtheria toxin A or its varian
Page 285 and 286:
17:3; 524-528; 2010 95 Lumachi F, L
Page 287 and 288:
130 Peranzoni E, Zilio S, Marigo I,
Page 289 and 290:
Surgery of the Alimentary Tract; 14
Page 291 and 292:
191 Zorzi M, Baracco S, Fedato C. L
Page 293 and 294:
ectal cancer: Pathologic results of
Page 295 and 296:
[as member of AIRTUM WG: Zambon P,
Page 297 and 298:
in laryngeal carcinoma treated with
Page 299 and 300:
G, Toland A E, Gerdes A M, Thomasse
Page 301 and 302:
european patients with central nerv
Page 303:
2011 PUBLICATIONS / Non indexed in
Page 306 and 307:
Index of Names A Alaibac Mauro 46,
Page 308 and 309:
Analytical Index A Acute Lymphoblas
Page 310:
Colophon Title: Scientific Report 2
show all

SCIENTIFIC REPORT 2010 - 2011 - IOV

Create successful ePaper yourself

Delete template?

Save as template?